Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke
Circulation · 13.01.2026 · 153 (2) · 86-93
DOI: 10.1161/circulationaha.125.077549 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 13.01.2026. Verfasst von Victorien Monguillon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Thrombolysis in Myocardial Infarction Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (V.M., M.L.O., J.-G.…. Hauptthemen laut MEDLINE: Cholesterol, LDL, Ischemic Stroke, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Amgen.
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: Patients with previous ischemic stroke are at high risk for recurrent stroke and other major adverse cardiovascular events. The benefits of achieving very low levels of low-density lipoprotein cholesterol (LDL-C) in such patients is unclear. METHODS: We analyzed patients with previous ischemic stroke enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), a randomized placebo-controlled trial studying evolocumab in patients with stable atherosclerotic cardiovascular disease (median follow-up, 2.2 years), and through the open-label extension (FOURIER-OLE) period (additional median follow-up, 5 years), to examine the relationship between achieved LDL-C and the long-term incidence of the primary end point (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina or coronary revascularization) and stroke-related end points. RESULTS: The analysis included 5291 patients with previous ischemic stroke (>4 weeks). Of these, 666 (12.6%), 1410 (26.6%), 586 (11.1%), 508 (9.6%), and 2121 (40.1%) patients achieved LDL-C values of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thrombolysis in Myocardial Infarction Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (V.M., M.L.O., J.-G.P., E.A.B., M.S.S., R.P.G.).
- Mater Misericordiae University Hospital, Dublin, Ireland (P.J.K.).
- School of Medicine, University College Dublin, Ireland (P.J.K.).
- Health Research Board Stroke Clinical Trials Network Ireland, Dublin (P.J.K.).
- Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine, University of California-Los Angeles (J.L.S.).
- Department of Cardiology, Oslo University Hospital Ulleval, Norway (D.A.).
ORCID-Profile: Victorien Monguillon, Peter J Kelly, Michelle L O'Donoghue, Jeong-Gun Park, Erin A Bohula, Jeffrey L Saver, Dan Atar, Anthony C Keech, Peter S Sever, Gabriel Paiva da Silva Lima, Marc S Sabatine, Robert P Giugliano
Förderung
- Amgen
Zitieren
APA
Monguillon, V., Kelly, P. J., O'Donoghue, M. L., Park, J. G., Bohula, E. A., Saver, J. L., Atar, D., Keech, A. C., Sever, P. S., Wang, H., Paiva da Silva Lima, G., Sabatine, M. S., & Giugliano, R. P. (2026). Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke. Circulation, 153(2), 86-93. https://doi.org/10.1161/circulationaha.125.077549
Vancouver
Monguillon V, Kelly PJ, O'Donoghue ML, Park JG, Bohula EA, Saver JL, et al. Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke. Circulation. 2026;153(2):86-93. doi:10.1161/circulationaha.125.077549
BibTeX
@article{Monguillon2026,
author = {Monguillon, Victorien and Kelly, Peter J and O'Donoghue, Michelle L and Park, Jeong-Gun and Bohula, Erin A and Saver, Jeffrey L and Atar, Dan and Keech, Anthony C and Sever, Peter S and Wang, Huei and Paiva da Silva Lima, Gabriel and Sabatine, Marc S and Giugliano, Robert P},
title = {Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke},
journal = {Circulation},
year = {2026},
volume = {153},
number = {2},
pages = {86--93},
doi = {10.1161/circulationaha.125.077549}
}
EUVIMED